Physician

Giuseppe Palermo, M.D.

According to 2025 Medicare claims, Giuseppe Palermo, M.D. (NPI: 1962507863) practices hematology/oncology in the Palm Bay-Melbourne-Titusville, FL market, with the plurality of this provider's patient population coming from Brevard, FL. This provider's primary affiliated billing organization is CANCER CARE CENTERS OF BREVARD INC (NPI: 1467551762; TIN: 593169766) and primary practice location at 32955-3229. Palermo is affiliated with the Mission Health Partners, LLC (ACO ID: A2591) and Primary Care Alliance, LLC (ACO ID: D0010), participating under both the MSSP and REACH models.

Palermo's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 769 traditional Medicare patients, billed 217,185 HCPCS/CPT codes, and received $3,597,830 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 2,047 prescription claims across 370 beneficiaries totaling $4,997,115 in drug costs, led by Imbruvica (Ibrutinib). DME data shows 24 claims. Open Payments data shows 346 records totaling $12,603. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $2,422,704 to $3,597,830. Similarly, Part D prescription costs have moved sharply higher in recent years, from $1,241,319 to $4,997,115. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $12,818 to $3,971.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,431	241,475	$2,422,704
2016	1,499	254,809	$2,433,167
2017	1,115	182,972	$2,081,773
2018	815	223,234	$2,577,510
2019	795	236,615	$2,449,155
2020	799	249,871	$3,013,878
2021	839	314,900	$3,892,080
2022	810	283,675	$3,528,056
2023	826	221,224	$3,319,158
2024	769	217,185	$3,597,830

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	209	1,278	$1,241,319
2016	235	1,480	$1,824,793
2017	235	1,348	$2,172,441
2018	312	1,702	$2,371,582
2019	293	1,855	$2,919,714
2020	312	1,840	$2,863,700
2021	347	2,010	$3,114,600
2022	352	2,142	$4,270,093
2023	374	2,204	$4,713,686
2024	370	2,047	$4,997,115

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	137	$21,211
2016	N/R	60	$16,421
2017	N/R	43	$1,777
2018	N/R	62	$6,731
2019	N/R	46	$1,202
2020	N/R	N/R	N/R
2021	N/R	68	$2,371
2022	N/R	199	$83,985
2023	N/R	36	$5,620
2024	N/R	24	$640

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	128	531	$100
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	498	955	$100
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	259	402	$72
36415	Insertion of needle into vein for collection of blood sample	240	554	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	326	1,071	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	42	1,188	$532,207
Xtandi	Enzalutamide	40	1,185	$528,667
Jakafi	Ruxolitinib Phosphate	27	795	$453,439
Tasigna	Nilotinib Hcl	22	602	$422,692
Tagrisso	Osimertinib Mesylate	21	630	$333,566

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	11	$415
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	13	$226

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	343	$11,478	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	3	$1,125	E.R. Squibb & Sons, L.L.C.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Giuseppe Palermo, M.D.?

Tedicare shows public-source Medicare data for Giuseppe Palermo, M.D. (NPI 1962507863), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Giuseppe Palermo, M.D. have ACO affiliation data?

Giuseppe Palermo, M.D. is shown with ACO affiliation data for Mission Health Partners, LLC (MSSP, ACO ID A2591) and Primary Care Alliance, LLC (REACH, ACO ID D0010).

What billing organization is linked to Giuseppe Palermo, M.D.?

Giuseppe Palermo, M.D. is linked to CANCER CARE CENTERS OF BREVARD INC (billing NPI 1467551762) in the available physician profile data.

Does Giuseppe Palermo, M.D. have Open Payments data?

Giuseppe Palermo, M.D. has 346 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.